Clinical Trials Logo

Giant Cell Tumors clinical trials

View clinical trials related to Giant Cell Tumors.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06331104 Completed - Giant Cell Tumors Clinical Trials

Network Pharmacology Prediction: Mechanism Study of Puerarin in the Treatment of Giant Cell Tumors of Bone

Start date: June 14, 2012
Phase:
Study type: Observational

Based on network pharmacology analysis, this study aims to explore the potential therapeutic targets and molecular mechanisms of puerarin on giant cell tumor of bone (GCTB) genes.

NCT ID: NCT05542524 Completed - Giant Cell Tumors Clinical Trials

Oral Care of Patients Treated With Anti-RANK-ligand Antibodies for a Giant Cell Tumour

DENO
Start date: September 1, 2022
Phase:
Study type: Observational

Giant cell tumors are mostly benign tomoral processes, most often responsible for areas of osteolysis in the metaphysoepiphyseal area of long bones, representing 5-6% of primary bone tumors. The bone weakening induced by these beaches leads to pain and risk of fracture, and this is what leads the patient to consult. These tumors are found particularly in the young adult population between 20 and 40 years old, are locally aggressive, but malignant transformations and metastases (pulmonary) are quite rare. In this study, the investigators wish to retrospectively study the oral care of patients who presented with a giant cell tumor and were treated with Denosumab at the University Hospital of Strasbourg and their associated oral follow-up

NCT ID: NCT05402865 Completed - Clinical trials for Giant Cell Tumor of Bone

A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone

Start date: November 10, 2021
Phase:
Study type: Observational

This is a retrospective observational real-world study, which evaluates the efficacy and safety of denosumab and non-denosumab therapies in the treatment of Chinese populations of surgically unsalvageable or severe post-surgery morbidity associated giant cell tumor of bone (GCTB), collectively referred to as unresectable GCTB, during 2013-2021 in three medical centers, serving as the external control for a single arm phase Ib/II trial on JMT103 treatment of GCTB. 301 patients were enrolled and divided into 2 groups according to their actual previous exposures. Group 1 (n=135) was denosumab group. Group 2 (n=166) included two types of exposures other than denosumab: other anti-GCTB drug therapies, or no therapy on GCTB patients. The dosage, route, frequency and other administration methods was collected according to the actual previous treatment records. The primary outcome measure was the tumor response rate [radiographic tumor response (CR/PR evaluated by ICDs or EORTC criteria) within 12 weeks, or at least 90% reduction of osteoclast like giant cells compared with baseline]. The key secondary endpoint was the tumor response rate [radiographic tumor response (CR/PR evaluated by ICDS or EORTC criteria), or at least 90% reduction of osteoclast like giant cells compared with baseline]. Other secondary Outcome Measures include: proportion of patients whose tumors was surgically resectable; median duration of tumor response (DOR), disease control rate (DCR), and time to disease progression (TTP); and types and proportion of key adverse reactions.

NCT ID: NCT04952818 Completed - Spinal Tumor Clinical Trials

The Value of Preoperative Diagnosis and Prognostic Prediction Based on Radiomics of Giant Cell Tumor of Spine

Start date: January 1, 2020
Phase:
Study type: Observational

1. Exploit CT (plain scan), enhanced CT and fMRI based radiomic biomarkers, explore their correlation with the prognostic molecular markers of spinal GCTB(p53/vegf/rank/rankl…), and help accurate diagnosis of GCTB. 2. Exploring a new method of preoperative risk stratification for spinal GCTB, and establishing radiomic model combined with clinical features. Exploring the GCTB biological behavior prediction model and the prognosis prediction of GCTB.

NCT ID: NCT04526704 Completed - Clinical trials for Tenosynovial Giant Cell Tumor

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

PLX3397
Start date: October 20, 2020
Phase: Phase 4
Study type: Interventional

This study is designed to evaluate the discontinuation/re-treatment of pexidartinib therapy in previously treated participants with tenosynovial giant cell tumor (TGCT).

NCT ID: NCT04002817 Completed - Clinical trials for Giant Cell Tumor of Bone

Giant Cell Tumor of the Bone in Young Patients

Start date: June 5, 2019
Phase:
Study type: Observational

single institution cases series review of histological and clinical data of young patient with Giant Cell Tumors

NCT ID: NCT03301857 Completed - Clinical trials for Giant Cell Tumor of Bone

Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004

Start date: November 13, 2017
Phase: Phase 4
Study type: Interventional

Study 20140114 will continue to follow participants with GCTB who were treated in Study 20062004 and remained on the study at the completion of Study 20062004 for an additional 5 years on long-term safety follow up.

NCT ID: NCT02996734 Completed - Clinical trials for Giant Cell Tumor of Bone

Giant Cell Tumor of the Extremities Treated With Surgery and/or Medical Treatment

GCTLIMBS
Start date: April 2016
Phase: N/A
Study type: Observational

The purpose of this project is to present the outcomes of patients with giant cell tumor of bone (GCTB) who were treated with surgery and/or medical treatment in a single institution.

NCT ID: NCT02948088 Completed - Giant Cell Tumors Clinical Trials

Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project

TOP
Start date: November 18, 2016
Phase:
Study type: Observational [Patient Registry]

TGCT is a rare disease that is difficult to manage, surgical resection is the primary treatment currently available. To date no disease registry exists and there is little data available detailing the management of patients with diffuse TGCT (d-TGCT), the burden of d-TGCT for patients (including pain, joint stiffness, swelling, reduced mobility and quality of life) or the economic impact of d-TGCT. This study aims to collect data by an observational disease registry involving no intervention to the patient or changes to investigators treatment decisions.

NCT ID: NCT02471716 Completed - Clinical trials for Tenosynovial Giant Cell Tumor

Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor

FPA008-002
Start date: June 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2 single arm, open-label, safety, tolerability, and PK study of cabiralizumab in PVNS/dt-TGCT patients.